Physician profile
Ryan Wier
NPI 1679204242
$7,100.55
in general payments reported to CMS, 2019-2025
20 companies · $320 in 2025
The $320 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,318 · 2023: $2,885 · 2024: $2,578 · 2025: $320.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,782.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,782.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $2,502.65 | 2022-2025 | Dovato, Apretude, Cabenuva |
| Gilead Sciences, INC. | $2,181.68 | 2022-2025 | Descovy |
| Theratechnologies INC. | $462.18 | 2022-2024 | Trogarzo, Egrifta |
| Pfizer INC. | $439.95 | 2022-2024 | |
| Abbvie INC. | $310.88 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $234.32 | 2022-2024 | Delstrigo, Pifeltro, Gardasil 9 |
| Idorsia Pharmaceuticals US INC | $191.19 | 2022-2024 | Quviviq |
| Napo Pharmaceuticals INC | $156.07 | 2022-2023 | Mytesi |
| Otsuka America Pharmaceutical, INC. | $146.39 | 2022-2024 | Rexulti |
| Lilly USA, LLC | $71.73 | 2023-2024 | Mounjaro, Emgality, Reyvow |
| Janssen Biotech, INC. | $63.31 | 2023 | Symtuza |
| Amgen INC. | $59.33 | 2024 | Repatha, Otezla |
| Hologic Sales and Service, LLC | $49.31 | 2024 | Aptima |
| Biohaven Pharmaceutical Holding Company Ltd. | $45.24 | 2022 | |
| Exact Sciences Corporation | $41.57 | 2023 | Cologuard Collection Kit |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $41.45 | 2024 | Rexulti |
| Novo Nordisk INC | $37.54 | 2023-2024 | Wegovy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $30.66 | 2023 | Xifaxan |
| E.R. Squibb & Sons, L.L.C. | $19.96 | 2024 | Eliquis |
| Antares Pharma, INC. | $15.14 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Wier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.